Medpace Holdings, Inc. (MEDP) Net Income CAGR:10.57%(TTM)
Net income CAGR uses precomputed financial statement history.
Over longer horizons, Medpace Holdings, Inc.'s Net Income CAGR averages 21.45% over 3 years and 23.58% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Net income CAGR shows how Medpace Holdings, Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
MEDP Net Income CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 20 quarters.
MEDP Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $404.39M | $451.12M | +$46.74M | +11.56% | +11.56% |
| 2024 | $282.81M | $404.39M | +$121.58M | +42.99% | +42.99% |
| 2023 | $245.37M | $282.81M | +$37.44M | +15.26% | +15.26% |
| 2022 | $181.85M | $245.37M | +$63.52M | +34.93% | +34.93% |
| 2021 | $145.38M | $181.85M | +$36.46M | +25.08% | +25.08% |
| 2020 | $100.44M | $145.38M | +$44.94M | +44.74% | +44.74% |
| 2019 | $73.19M | $100.44M | +$27.26M | +37.25% | +37.25% |
| 2018 | $39.12M | $73.19M | +$34.06M | +87.07% | +87.07% |
| 2017 | $13.43M | $39.12M | +$25.70M | +191.41% | +191.41% |
| 2016 | $-8.67M | $13.43M | +$22.10M | N/A | N/A |
| 2015 | $-15.57M | $-8.67M | +$6.90M | N/A | N/A |
| 2014 | $24.84M | $-15.57M | $-40.42M | -162.68% | N/A |
Quarterly Net Income: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $123.87M | -8.3% | +8.1% |
| Q4 2025 | $135.13M | +21.6% | +15.5% |
| Q3 2025 | $111.14M | +23.1% | +15.3% |
| Q2 2025 | $90.26M | -21.2% | +2.2% |
| Q1 2025 | $114.59M | -2.1% | +11.7% |
| Q4 2024 | $117.02M | +21.4% | +49.5% |
| Q3 2024 | $96.43M | +9.1% | +36.7% |
| Q2 2024 | $88.35M | -13.9% | +44.7% |
| Q1 2024 | $102.59M | +31.0% | +40.7% |
| Q4 2023 | $78.30M | +11.0% | +14.0% |
| Q3 2023 | $70.55M | +15.5% | +6.9% |
| Q2 2023 | $61.07M | -16.2% | +23.7% |
| Q1 2023 | $72.89M | +6.2% | +18.9% |
| Q4 2022 | $68.67M | +4.0% | +37.2% |
| Q3 2022 | $66.03M | +33.8% | +35.9% |
| Q2 2022 | $49.36M | -19.5% | +23.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle